Gypenosides Alleviate Hyperglycemia by Regulating Gut Microbiota Metabolites and Intestinal Permeability

<b>Background/Objectives</b>: Gypenosides (Gps) are the main active compounds of <i>Gynostemma</i> and show promise in managing diabetes; nevertheless, the mechanism by which Gps exert anti-diabetic effects is still not fully understood. The aim of this study is to clarify th...

Full description

Saved in:
Bibliographic Details
Main Authors: Rong Wang, Xue-Feng Liu, Kuan Yang, Li-Li Yu, Shao-Jing Liu, Na-Na Wang, Yun-Mei Chen, Ya-Qi Hu, Bei Qin
Format: Article
Language:English
Published: MDPI AG 2025-07-01
Series:Current Issues in Molecular Biology
Subjects:
Online Access:https://www.mdpi.com/1467-3045/47/7/515
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849733337527091200
author Rong Wang
Xue-Feng Liu
Kuan Yang
Li-Li Yu
Shao-Jing Liu
Na-Na Wang
Yun-Mei Chen
Ya-Qi Hu
Bei Qin
author_facet Rong Wang
Xue-Feng Liu
Kuan Yang
Li-Li Yu
Shao-Jing Liu
Na-Na Wang
Yun-Mei Chen
Ya-Qi Hu
Bei Qin
author_sort Rong Wang
collection DOAJ
description <b>Background/Objectives</b>: Gypenosides (Gps) are the main active compounds of <i>Gynostemma</i> and show promise in managing diabetes; nevertheless, the mechanism by which Gps exert anti-diabetic effects is still not fully understood. The aim of this study is to clarify the molecular mechanisms of Gps in ameliorating glucose dysregulation. <b>Methods</b>: Qualitative and quantitative analyses on the chemical components of Gps were performed, respectively. Type 2 diabetes mellitus mouse models were established, and the mice were subsequently treated with Gps at doses of 200, 100, or 50 mg/kg for 4 weeks. Biochemical markers were measured. Histopathological assessments of hepatic and colonic tissues were conducted. The compositions of the intestinal microbiota, short-chain fatty acids (SCFAs), and bile acids (BAs) in fecal samples were analyzed. Western blotting was applied to examine the activation of relevant signaling pathways. <b>Results</b>: Gps have potent regulatory effects on metabolic homeostasis by improving glucose and lipid profiles and alleviating hepatic tissue damage. Treatment with Gps significantly reduced serum levels of lipopolysaccharides and key pro-inflammatory cytokines (interleukin-6 and tumor necrosis factor-α). Moreover, Gps enhanced the integrity of the gut barrier by upregulating the level of tight junction proteins (ZO-1 and occludin). Microbiota profiling revealed that Gps markedly increased microbial diversity and richness, decreased the ratio of <i>Firmicutes</i>/<i>Bacteroidetes</i>, and elevated <i>Bacteroidia</i> abundance from the phylum to the genus level. Targeted metabolomics further demonstrated that Gps modulated gut microbial metabolites by promoting SCFA production and reshaping BA profiles. Specifically, Gps elevated the primary-to-secondary BA ratio while reducing the 12α-hydroxylated to non-12α-hydroxylated BA ratio. Mechanistically, Western blotting demonstrated that Gps triggered the hepatic PI3K/AKT pathway and the intestinal BA/FXR/FGF15 axis, suggesting the coordinated regulation of metabolic and gut–liver axis signaling pathways. <b>Conclusions</b>: Gps significantly ameliorate hyperglycemia and hyperlipidemia through a multifaceted mechanism involving gut microbiota modulation, the restoration of intestinal barrier function, and the regulation of microbial metabolites such as SCFAs and BAs. These findings offer novel insights into their mechanism of action via the gut–liver axis.
format Article
id doaj-art-2abf9caf03784c33ae3ef1f1042e5111
institution DOAJ
issn 1467-3037
1467-3045
language English
publishDate 2025-07-01
publisher MDPI AG
record_format Article
series Current Issues in Molecular Biology
spelling doaj-art-2abf9caf03784c33ae3ef1f1042e51112025-08-20T03:08:05ZengMDPI AGCurrent Issues in Molecular Biology1467-30371467-30452025-07-0147751510.3390/cimb47070515Gypenosides Alleviate Hyperglycemia by Regulating Gut Microbiota Metabolites and Intestinal PermeabilityRong Wang0Xue-Feng Liu1Kuan Yang2Li-Li Yu3Shao-Jing Liu4Na-Na Wang5Yun-Mei Chen6Ya-Qi Hu7Bei Qin8Xi’an Key Laboratory for Research and Development of Innovative Multi-Target Anti-Hypertensive Drugs, Xi’an Medical University, Xi’an 710021, ChinaShaanxi Institute of Food and Drug Control, Xi’an 710021, ChinaXi’an Key Laboratory for Research and Development of Innovative Multi-Target Anti-Hypertensive Drugs, Xi’an Medical University, Xi’an 710021, ChinaXi’an Key Laboratory for Research and Development of Innovative Multi-Target Anti-Hypertensive Drugs, Xi’an Medical University, Xi’an 710021, ChinaXi’an Key Laboratory for Research and Development of Innovative Multi-Target Anti-Hypertensive Drugs, Xi’an Medical University, Xi’an 710021, ChinaXi’an Key Laboratory for Research and Development of Innovative Multi-Target Anti-Hypertensive Drugs, Xi’an Medical University, Xi’an 710021, ChinaXi’an Key Laboratory for Research and Development of Innovative Multi-Target Anti-Hypertensive Drugs, Xi’an Medical University, Xi’an 710021, ChinaXi’an Key Laboratory for Research and Development of Innovative Multi-Target Anti-Hypertensive Drugs, Xi’an Medical University, Xi’an 710021, ChinaXi’an Key Laboratory for Research and Development of Innovative Multi-Target Anti-Hypertensive Drugs, Xi’an Medical University, Xi’an 710021, China<b>Background/Objectives</b>: Gypenosides (Gps) are the main active compounds of <i>Gynostemma</i> and show promise in managing diabetes; nevertheless, the mechanism by which Gps exert anti-diabetic effects is still not fully understood. The aim of this study is to clarify the molecular mechanisms of Gps in ameliorating glucose dysregulation. <b>Methods</b>: Qualitative and quantitative analyses on the chemical components of Gps were performed, respectively. Type 2 diabetes mellitus mouse models were established, and the mice were subsequently treated with Gps at doses of 200, 100, or 50 mg/kg for 4 weeks. Biochemical markers were measured. Histopathological assessments of hepatic and colonic tissues were conducted. The compositions of the intestinal microbiota, short-chain fatty acids (SCFAs), and bile acids (BAs) in fecal samples were analyzed. Western blotting was applied to examine the activation of relevant signaling pathways. <b>Results</b>: Gps have potent regulatory effects on metabolic homeostasis by improving glucose and lipid profiles and alleviating hepatic tissue damage. Treatment with Gps significantly reduced serum levels of lipopolysaccharides and key pro-inflammatory cytokines (interleukin-6 and tumor necrosis factor-α). Moreover, Gps enhanced the integrity of the gut barrier by upregulating the level of tight junction proteins (ZO-1 and occludin). Microbiota profiling revealed that Gps markedly increased microbial diversity and richness, decreased the ratio of <i>Firmicutes</i>/<i>Bacteroidetes</i>, and elevated <i>Bacteroidia</i> abundance from the phylum to the genus level. Targeted metabolomics further demonstrated that Gps modulated gut microbial metabolites by promoting SCFA production and reshaping BA profiles. Specifically, Gps elevated the primary-to-secondary BA ratio while reducing the 12α-hydroxylated to non-12α-hydroxylated BA ratio. Mechanistically, Western blotting demonstrated that Gps triggered the hepatic PI3K/AKT pathway and the intestinal BA/FXR/FGF15 axis, suggesting the coordinated regulation of metabolic and gut–liver axis signaling pathways. <b>Conclusions</b>: Gps significantly ameliorate hyperglycemia and hyperlipidemia through a multifaceted mechanism involving gut microbiota modulation, the restoration of intestinal barrier function, and the regulation of microbial metabolites such as SCFAs and BAs. These findings offer novel insights into their mechanism of action via the gut–liver axis.https://www.mdpi.com/1467-3045/47/7/515gypenosidestype 2 diabetes mellitusgut microbiotashort-chain fatty acidsbile acids
spellingShingle Rong Wang
Xue-Feng Liu
Kuan Yang
Li-Li Yu
Shao-Jing Liu
Na-Na Wang
Yun-Mei Chen
Ya-Qi Hu
Bei Qin
Gypenosides Alleviate Hyperglycemia by Regulating Gut Microbiota Metabolites and Intestinal Permeability
Current Issues in Molecular Biology
gypenosides
type 2 diabetes mellitus
gut microbiota
short-chain fatty acids
bile acids
title Gypenosides Alleviate Hyperglycemia by Regulating Gut Microbiota Metabolites and Intestinal Permeability
title_full Gypenosides Alleviate Hyperglycemia by Regulating Gut Microbiota Metabolites and Intestinal Permeability
title_fullStr Gypenosides Alleviate Hyperglycemia by Regulating Gut Microbiota Metabolites and Intestinal Permeability
title_full_unstemmed Gypenosides Alleviate Hyperglycemia by Regulating Gut Microbiota Metabolites and Intestinal Permeability
title_short Gypenosides Alleviate Hyperglycemia by Regulating Gut Microbiota Metabolites and Intestinal Permeability
title_sort gypenosides alleviate hyperglycemia by regulating gut microbiota metabolites and intestinal permeability
topic gypenosides
type 2 diabetes mellitus
gut microbiota
short-chain fatty acids
bile acids
url https://www.mdpi.com/1467-3045/47/7/515
work_keys_str_mv AT rongwang gypenosidesalleviatehyperglycemiabyregulatinggutmicrobiotametabolitesandintestinalpermeability
AT xuefengliu gypenosidesalleviatehyperglycemiabyregulatinggutmicrobiotametabolitesandintestinalpermeability
AT kuanyang gypenosidesalleviatehyperglycemiabyregulatinggutmicrobiotametabolitesandintestinalpermeability
AT liliyu gypenosidesalleviatehyperglycemiabyregulatinggutmicrobiotametabolitesandintestinalpermeability
AT shaojingliu gypenosidesalleviatehyperglycemiabyregulatinggutmicrobiotametabolitesandintestinalpermeability
AT nanawang gypenosidesalleviatehyperglycemiabyregulatinggutmicrobiotametabolitesandintestinalpermeability
AT yunmeichen gypenosidesalleviatehyperglycemiabyregulatinggutmicrobiotametabolitesandintestinalpermeability
AT yaqihu gypenosidesalleviatehyperglycemiabyregulatinggutmicrobiotametabolitesandintestinalpermeability
AT beiqin gypenosidesalleviatehyperglycemiabyregulatinggutmicrobiotametabolitesandintestinalpermeability